LUMEDX Announces Industry Partnership With MedAxiom

Leaders in business intelligence and the cardiovascular space use knowledge exchange and thought leadership in working towards better care and lower costs

OAKLAND, Calif.–(BUSINESS WIRE)–#healthcare–LUMEDX, a market leader in cardiovascular information systems (CVIS) and cutting-edge business intelligence solutions for more than 25 years, is excited to announce its industry partnership with MedAxiom, the nation’s leading cardiovascular healthcare membership organization and community.

“We are excited to work with MedAxiom towards our shared goal of improving cardiovascular care,” said LUMEDX Co-Founder and CEO Allyn McAuley. “Through the Cardiovascular Performance Program, our HealthView Analytics (HVA) platform is currently providing leading U.S. institutions with meaningful insights that are driving better patient outcomes and significant cost savings.”

MedAxiom was acquired earlier this year by the American College of Cardiology but continues to operate as a wholly owned, but separately incorporated, for-profit enterprise. From exclusive data and data analytics to program excellence tools and world-class educational events, MedAxiom is dedicated to improving business and patient care outcomes for the cardiovascular community through knowledge sharing and thought leadership.

“LUMEDX is well known for their CVIS products and performance analytics—helping organizations manage costs, quality, and workflows with HVA,” said Joe Sasson Ph.D., EVP of MedAxiom Ventures. “We are excited to welcome them as a MedAxiom Industry Partner and bring this powerful product to our membership community.”

LUMEDX clients will have an opportunity to learn more about MedAxiom at the CV TransForum Fall ’19 conference, October 24-26, in Dana Point, CA.

About MedAxiom

MedAxiom, an American College of Cardiology company, is the cardiovascular community’s largest membership and resources network and the leading cardiovascular-specific consulting team in the United States. MedAxiom is transforming cardiovascular care by combining the knowledge and power of more than 400 cardiovascular organization members and thousands of providers, administrators, and clinicians. Through the delivery of proprietary tools, smart data and proven strategies, MedAxiom helps cardiovascular organizations achieve the Quadruple Aim of better outcomes, lower costs, improved patient experience, and improved clinician experience. For more information, visit www.MedAxiom.com.

About LUMEDX

LUMEDX is a leader in cardiovascular data intelligence and cardiovascular information systems (CVIS). In business for over 25 years with a track record of serving more than 600 hospitals, the company offers an end-to-end suite of software and services that enable embedded analytics at the point of care, high performance workflows, optimal integration of clinical and EHR data, and improved continuity of care. Learn more at https://www.lumedx.com/

Contacts

Gabriela Barragan

(510) 590-3189

gabriela.barragan@lumedx.com

Staff

Recent Posts

Creative Medical Technology Holdings Provides Corporate Update

PHOENIX--(BUSINESS WIRE)--Creative Medical Technology Holdings, Inc., (“Creative Medical Technology” or the “Company”) (NASDAQ: CELZ), a…

15 mins ago

GE HealthCare Unveils AI-Enabled Urology Software Feature Prostate Volume Assist

Prostate Volume Assist (PVA) is the company’s proprietary urology-based artificial intelligence (AI) software feature designed…

16 mins ago

Sutter Health Partners with Abridge on Generative AI Solution to Improve Patient, Physician Experience

PITTSBURGH & SACRAMENTO, Calif.--(BUSINESS WIRE)--Today, Abridge and Sutter Health announced they will make Abridge’s generative…

17 mins ago

Bausch + Lomb Will Present New Scientific Data and Analyses at the American Society of Cataract and Refractive Surgery Annual Meeting

Presentations Will Feature Studies Evaluating TENEO™ Excimer Laser Platform, MIEBO® (Perfluorohexyloctane Ophthalmic Solution) and enVista®…

18 mins ago

Blackstone Life Sciences Announces Collaboration to Support Moderna’s Influenza Program

Blackstone Life Sciences to invest up to $750 million to support innovative mRNA technologyNEW YORK--(BUSINESS…

19 mins ago

Male Contraceptive Initiative Marks Women’s History Month With Investment in Birth Control Pill for Men

Phase 1a study of first hormone-free male pill completes enrollmentDURHAM, NC / ACCESSWIRE / March…

20 mins ago